|
1
|
NL SS Harris, Jaffe ES, Ott G, Nathwani
BN, et al: World Health Organization Classification of Tumours, WHO
Classification of Tumours of Haematopoietic and Lymphoid Tissues.
4th. International Agency for Research on Cancer (IARC); Lyon: pp.
220–226. 2008
|
|
2
|
Lai R, Arber DA, Chang KL, Wilson CS and
Weiss LM: Frequency of bcl-2 expression in non-Hodgkin's lymphoma:
A study of 778 cases with comparison of marginal zone lymphoma and
monocytoid B-cell hyperplasia. Mod Pathol. 11:864–869.
1998.PubMed/NCBI
|
|
3
|
Takata K, Tanino M, Ennishi D, Tari A,
Sato Y, Okada H, Maeda Y, Goto N, Araki H, Harada M, et al:
Duodenal follicular lymphoma: Comprehensive gene expression
analysis with insights into pathogenesis. Cancer Sci. 1015:608–615.
2014. View Article : Google Scholar
|
|
4
|
Morishita H and Yagi T: Protocadherin
family: Diversity, structure, and function. Curr Opin Cell Biol.
19:584–592. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen WV, Alvarez FJ, Lefebvre JL, Friedman
B, Nwakeze C, Geiman E, Smith C, Thu CA, Tapia JC, Tasic B, et al:
Functional significance of isoform diversification in the
protocadherin gamma gene cluster. Neuron. 75:402–409. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu J, Koujak S, Nagase S, Li CM, Su T,
Wang X, Keniry M, Memeo L, Rojtman A, Mansukhani M, et al: PCDH8,
the human homolog of PAPC, is a candidate tumor suppressor of
breast cancer. Oncogene. 27:4657–4665. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Tayrac M, Etcheverry A, Aubry M,
Saïkali S, Hamlat A, Quillien V, Le Treut A, Galibert MD and Mosser
J: Integrative genome-wide analysis reveals a robust genomic
glioblastoma signature associated with copy number driving changes
in gene expression. Genes Chromosomes and Cancer. 48:55–68. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Haruki S, Imoto I, Kozaki K, Matsui T,
Kawachi H, Komatsu S, Muramatsu T, Shimada Y, Kawano T and Inazawa
J: Frequent silencing of protocadherin 17, a candidate tumour
suppressor for esophageal squamous-cell carcinoma. Carcinogenesis.
31:1027–1036. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ying J, Gao Z, Li H, Srivastava G, Murray
PG, Goh HK, Lim CY, Wang Y, Marafioti T, Mason DY, et al: Frequent
epigenetic silencing of protocadherin 10 by methylation in multiple
haematologic malignancies. Br J Haematol. 136:829–832. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hayashi E, Takata K, Sato Y, Tashiro Y,
Tachiyama Y, Sawada-Kitamura S, Hiramatsu Y, Sugiguchi S, Nose S,
Hirokawa M, et al: Distinct morphologic, phenotypic, and
clinical-course characteristics of indolent peripheral T-cell
lymphoma. Hum Pathol. 44:1927–1936. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takata K, Sato Y, Nakamura N, Tokunaka M,
Miki Y, Kikuti Y Yukie, Igarashi K, Ito E, Harigae H, Kato S, et
al: Duodenal follicular lymphoma lacks AID but expresses BACH2 and
has memory B-cell characteristics. Mod Pathol. 26:22–31. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Curtin JF and Cotter TG: Live and let die:
Regulatory mechanisms in Fas-mediated apoptosis. Cell Signal.
15:983–992. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng L, Sharma R, Gaskin F, Fu SM and Ju
ST: A novel role of IL-2 in organ-specific autoimmune inflammation
beyond regulatory T cell checkpoint: Both IL-2 knockout and Fas
mutation prolong lifespan of Scurfy mice but by different
mechanisms. J Immunol. 179:8035–8041. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Leich E, Salaverria I, Bea S, Zettl A,
Wright G, Moreno V, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, et
al: Follicular lymphomas with and without translocation t(14;18)
differ in gene expression profiles and genetic alterations. Blood.
114:826–834. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Masir N, Campbell LJ, Goff LK, Jones M,
Marafioti T, Cordell J, Clear AJ, Lister TA, Mason DY and Lee AM:
BCL2 protein expression in follicular lymphomas with t(14;18)
chromosomal translocations. Br J Haematol. 144:716–725. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zamo A, Erdini F, Malerba G and Chilosi M:
Lack of expression of TUBB3 characterizes both BCL2-positive and
BCL2-negative follicular lymphoma. Mod Pathol. 27:808–813. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu Y, Guo E, Yu J, Xie Q and Chen J: High
DcR3 expression predicts stage pN2 in gastric cancer.
Hepatogastroenterology. 54:2172–2176. 2007.PubMed/NCBI
|
|
19
|
Connor JP and Felder M: Ascites from
epithelial ovarian cancer contain high levels of functional decoy
receptor 3 (DcR3) and is associated with platinum resistance.
Gynecol Oncol. 111:330–335. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weissinger D, Tagscherer KE,
Macher-Göppinger S, Haferkamp A, Wagener N and Roth W: The soluble
Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and
promotes migration and invasion in renal cell carcinoma. Mol
Cancer. 12:1202013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bedewy AM, Elgammal MM, Bedewy MM and
El-Maghraby SM: Assessing DcR3 expression in relation to survivin
and other prognostic factors in B cell non-Hodgkin's lymphoma. Ann
Hematol. 92:1359–1367. 2013. View Article : Google Scholar : PubMed/NCBI
|
